Journal of Nuclear Cardiology

, Volume 16, Issue 3, pp 478–480

Initial clinical experience with a selective A2A receptor agonist, regadenoson, in a patient with end-stage renal disease on hemodialysis

Authors

  • Saaron Laighold
    • Division of CardiologyNorth Shore University Hospital
    • Division of CardiologyNorth Shore University Hospital
Nuclear Cardiology Bullet

DOI: 10.1007/s12350-008-9043-z

Cite this article as:
Laighold, S. & Druz, R. J. Nucl. Cardiol. (2009) 16: 478. doi:10.1007/s12350-008-9043-z

Copyright information

© American Society of Nuclear Cardiology 2008